Literature DB >> 24114282

Disclosure pattern and follow-up after the molecular diagnosis of BRCA/CHEK2 mutations.

D Kegelaers1, W Merckx, P Odeurs, J van den Ende, B Blaumeiser.   

Abstract

Five to 10% of all breast cancer cases are due to mutations of high penetrance susceptibility genes, especially BRCA1 and BRCA2. In families with known BRCA mutations, disclosure of genetic test results could induce relatives to undergo genetic testing themselves and adopt cancer risk management strategies, if necessary. This study examines disclosure patterns of individuals tested for mutations in the BRCA1, BRCA2 and CHEK2 genes to first-degree relatives with emphasis on a possible gender difference. It also assesses which management strategy is preferred by mutation-positive women in Belgium and the influence of psychological characteristics on communication and choice of management strategy. Ninety-nine adults from BRCA/CHEK2 families, selected from the Centre of Medical Genetics of Antwerp, were included in the study. They were provided with medical and psychological questionnaires, the latter being the Self-Assessment Questionnaire, which is the Dutch version of the Spielberger State-Trait Anxiety Inventory and the Dutch version of the Coping Inventory for Stressful Situations (CISS-NL). The survey focused on disclosure, coping and management strategies with special attention on possible gender differences. The influence of socio-demographic and medical data on disclosure and cancer risk management as well as the influence of psychological features were examined by means of various statistical analyses. Ninety-nine patients were included, of whom 25 (25 %) were male. Eighty-seven percent of the participants informed all of their adult first-degree relatives about their mutation status without any gender discrimination. Seventy-eight percent of highly-educated participants informed all of their adult first-degree relatives, compared to 98 % of less formally-educated participants (p = 0.006). The majority of mutation-positive women preferred prophylactic surgery to surveillance. Psychological differences appeared to have little influence on disclosure patterns and management strategies. The gender difference seems to be less pronounced than previously assumed. A striking observation, however, is the fact that significantly more participants who were less formally-educated informed all of their adult first-degree relatives, compared to participants who were highly-educated. In our study population, most female mutation carriers opted for prophylactic surgery. Since the study population is small, further studies are needed to enhance the generalizability of these results.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114282     DOI: 10.1007/s10897-013-9656-5

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  16 in total

1.  Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing.

Authors:  Wendy McKinnon; Shelly Naud; Taka Ashikaga; Rose Colletti; Marie Wood
Journal:  J Genet Couns       Date:  2007-06-27       Impact factor: 2.537

Review 2.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Laurie Hoyt Huffman; Rongwei Fu; Emily L Harris
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

3.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Authors:  L C Hartmann; T A Sellers; D J Schaid; T S Frank; C L Soderberg; D L Sitta; M H Frost; C S Grant; J H Donohue; J E Woods; S K McDonnell; C W Vockley; A Deffenbaugh; F J Couch; R B Jenkins
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  K-A Phillips; M A Jenkins; G J Lindeman; S A McLachlan; J M McKinley; P C Weideman; J L Hopper; M L Friedlander
Journal:  Clin Genet       Date:  2006-09       Impact factor: 4.438

6.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

7.  Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

Authors:  Russell Hogg; Michael Friedlander
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

8.  Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations.

Authors:  Esme Finlay; Jill E Stopfer; Eric Burlingame; Katherine Goldfeder Evans; Katherine L Nathanson; Barbara L Weber; Katrina Armstrong; Timothy R Rebbeck; Susan M Domchek
Journal:  Genet Test       Date:  2008-03

9.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Authors:  Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

10.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.

Authors: 
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  6 in total

1.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

2.  The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer.

Authors:  Claire C Conley; Dana Ketcher; Maija Reblin; Monica L Kasting; Deborah Cragun; Jongphil Kim; Kimlin Tam Ashing; Cheryl L Knott; Chanita Hughes-Halbert; Tuya Pal; Susan T Vadaparampil
Journal:  J Genet Couns       Date:  2020-01-07       Impact factor: 2.537

3.  Patients' Attitudes Towards Disclosure of Genetic Test Results to Family Members: The Impact of Patients' Sociodemographic Background and Counseling Experience.

Authors:  Roy Gilbar; Stavit Shalev; Ronen Spiegel; Elon Pras; Michal Berkenstadt; Michal Sagi; Adi Ben-Yehuda; Pnina Mor; Shlomit Perry; Tzipora Falik Zaccai; Zvi Borochowitz; Sivia Barnoy
Journal:  J Genet Couns       Date:  2015-09-14       Impact factor: 2.537

4.  Impact of a randomized controlled educational trial to improve physician practice behaviors around screening for inherited breast cancer.

Authors:  Robert A Bell; Haley McDermott; Tonya L Fancher; Michael J Green; Frank C Day; Michael S Wilkes
Journal:  J Gen Intern Med       Date:  2014-12-02       Impact factor: 5.128

5.  Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.

Authors:  Annemieke Witteveen; Ingrid M H Vliegen; Gabe S Sonke; Joost M Klaase; Maarten J IJzerman; Sabine Siesling
Journal:  Breast Cancer Res Treat       Date:  2015-07-11       Impact factor: 4.872

6.  Increasing confidence and changing behaviors in primary care providers engaged in genetic counselling.

Authors:  Michael S Wilkes; Frank C Day; Tonya L Fancher; Haley McDermott; Erik Lehman; Robert A Bell; Michael J Green
Journal:  BMC Med Educ       Date:  2017-09-13       Impact factor: 2.463

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.